Form 4: SeaStar Medical CEO Eric Schlorff Reports RSU Vesting and Share Ownership Update Post Reverse Stock Split

SeaStar Medical Holding Corp.'s CEO, Eric Schlorff, reported the vesting of 21,667 restricted stock units into common stock, adjusting his beneficial ownership to 98,517 shares following a 1-for-25 reverse stock split.

Summary

• Eric Schlorff, Chief Executive Officer and Director of SeaStar Medical Holding Corp. (ICU), reported changes in his beneficial ownership of company stock.
• On July 1, 2025, 21,667 restricted stock units (RSUs) vested and converted into shares of ICU common stock.
• These vested RSUs represent the first installment of a 65,000 RSU grant awarded on November 15, 2024, with vesting scheduled in three approximately equal annual installments starting July 1, 2024.
• Following this transaction, Schlorff's direct beneficial ownership of common stock is 98,517 shares.
• All reported share amounts have been adjusted to reflect a 1-for-25 reverse stock split effectuated by SeaStar Medical on June 7, 2024.
• The total beneficial ownership of 98,517 shares includes 43,333 shares underlying unvested RSUs that were previously reported as derivative securities but are now included in the non-derivative securities table.

Sentiment

Score: 6

Explanation: The vesting of RSUs is a positive event for the executive, reflecting earned compensation. However, the context of a recent 1-for-25 reverse stock split, while an adjustment, often indicates a company facing challenges with its share price, which can be a negative signal for investors. The filing itself is a routine compliance report.

Positives

• Vesting of 21,667 restricted stock units indicates a successful milestone for the executive, converting contingent rights into actual shares.
• The transaction demonstrates continued alignment of management's interests with shareholders through equity ownership.

Negatives

• The disclosure of a 1-for-25 reverse stock split, while an adjustment, often signals underlying challenges such as a low share price or risk of delisting, which can be perceived negatively by investors.

Risks

• The 1-for-25 reverse stock split effectuated on June 7, 2024, may indicate a low share price or potential delisting concerns, which are inherent risks to shareholder value.

Future Outlook

The remaining unvested portions of the 65,000 RSU grant to Eric Schlorff are expected to vest in two approximately equal annual installments on the second and third anniversaries of July 1, 2024.

Industry Context

This Form 4 filing details an executive's equity compensation vesting and ownership adjustments, which is a routine disclosure in the financial industry. The mention of a reverse stock split, however, suggests the company may be addressing a low share price, a common strategy in the biotechnology or medical device sector (where SeaStar Medical operates) to maintain listing compliance or improve stock attractiveness, though it can also signal underlying financial challenges.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries, including the medical device sector.
• The vesting of executive equity compensation, such as RSUs, is a common practice in public companies, aligning executive incentives with shareholder value.
• Reverse stock splits, while not unique to the medical device industry, are often observed in smaller-cap or development-stage companies within this sector that may experience prolonged periods of low stock prices due to clinical trial timelines, regulatory hurdles, or market capitalization requirements for exchange listings. Specific comparable companies or projects are not mentioned in the document.

Stakeholder Impact

• Shareholders: The vesting of RSUs increases the number of outstanding shares, potentially leading to minor dilution, but also aligns executive interests with shareholder value. The reverse stock split impacts the number of shares held by existing shareholders and the per-share price, potentially improving market perception or listing compliance.
• Employees: No direct impact on general employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• Future vesting of the remaining 43,333 Restricted Stock Units (RSUs) granted on November 15, 2024, in two approximately equal annual installments on the second and third anniversaries of July 1, 2024.

Key Dates

Recommendation

Keywords

SeaStar Medical Holding Corp, ICU, Eric Schlorff, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSU vesting, Common Stock, Reverse Stock Split, Executive Compensation, Corporate Governance